WisdomTree US High Dividend ETF (DHS) focuses on high-yield, quality U.S. equities, favoring defensive sectors. Read an ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Summit, a specialist in oncology, has made excellent clinical progress with its leading candidate, ivonescimab. There's more where that came from, too; Ivonescimab just knocked it out of the park in ...

More than 80% of oncologists participating in a global survey consider insurance a major barrier to timely cancer care.

AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

Can ctDNA-guided therapy stop cancer’s return, sparing patients unnecessary treatment? A new study suggests it might.

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

The impact of the global tariffs war will cost GE Healthcare Technologies Inc. around $500 million in 2025 at current rates, with most of the impact coming in the second half of the year, the medical ...